Clin2
NCT07064018Possibly a fitRecruiting

SPEDOX-6 for advanced solid tumors

Soft-tissue SarcomaTriple Negative Breast CancerNon-small Cell Lung CancerCervical CancerOvarian CancerKRAS Mutation-Related Tumors

Treatments studied

Part of Cancer, Hormones & metabolism, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.

This trial tests a new form of the chemotherapy drug doxorubicin, called SPEDOX-6, for people with certain advanced solid tumors that haven't responded to at least two prior treatments. The drug is designed to deliver doxorubicin directly to cancer cells while possibly reducing side effects.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1/Phase 2
Enrollment
67 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • Your cancer must be one of these types: soft tissue sarcoma, triple-negative breast cancer, cervical cancer, non-small cell lung cancer, ovarian cancer, or pancreatic cancer with a KRAS mutation.
  • Your cancer has come back or gotten worse despite at least two prior treatments.
  • You have not had doxorubicin or any similar chemotherapy drug before.
  • You have no untreated brain metastases, and your heart and other organs are working well enough.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05985655Recruiting· Phase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors

This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.

Los Angeles, California
NCT03943004Recruiting· Phase 1
Study drug DFP-14927 for advanced solid tumors

This Phase 1 trial tests DFP-14927, a new study drug, in adults with advanced solid tumors that have not responded to standard treatments. It’s designed to see if the drug is safe and to learn how it works in people with limited treatment options.

Los Angeles, California
NCT06259552Recruiting· Phase 1
Study of SPX-303 for advanced solid tumors

This trial tests a new drug called SPX-303, which is designed to help your immune system fight cancer cells. It is for people with advanced solid tumors that have not responded to other treatments.

Phoenix, Arizona
NCT07532018Recruiting· Phase 1
DXP-106 Treatment for Advanced Solid Tumors

This early-stage trial tests a new drug called DXP-106 in patients with advanced cancers (like lung, pancreatic, or breast cancer) that have stopped responding to standard treatments. The study aims to find the right dose and see if this drug can help slow or shrink these tumors.

Harbin, Heilongjiang
NCT07391644Not yet recruiting· Phase 1
Testing JSKN027 for advanced solid tumors that have progressed

This trial tests a new drug called JSKN027 for people with advanced solid tumors (cancers that have spread) that have not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.

Beijing, Beijing Municipality
NCT06249048Recruiting· Phase 1/Phase 2
Study of STX-001 injection for advanced solid tumors

This trial tests a new drug called STX-001, which is injected directly into a tumor to help the immune system fight cancer. It is being studied alone or with another immunotherapy (pembrolizumab) for people with advanced solid tumors, including melanoma or triple-negative breast cancer.

Scottsdale, Arizona

Hear when a new Soft Tissue Sarcoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.